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ABSTRACT
Azithromycin (Zithromax(R), Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and
the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive
penetration into intracellular and interstitial tissue compartments, accompanied by prolonged
tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but
is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia
trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen
recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-
acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms.
Azithromycin provides short-duration, high-compliance, cost-effective regimens that should im-
prove outcomes. (C) 1997 Wiley-Liss, Inc.
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zithromycin (Zithromax(R), Pfizer, Inc., New
York, NY), the first azalide antibiotic, has been
approved for the single-dose treatment of nongono-
coccal urethritis and cervicitis due to Chlamydia tra-
chomatis. In addition, azithromycin is useful in a
5-day regimen for the treatment of indicated respi-
ratory-tract and skin and skin-structure infections
(Table 1) (unpublished data, Pfizer, Inc., 1996).
C. trachomatis is the most common sexually trans-
mitted pathogen in the United States. An obligate
intracellular parasite, C. trachomatis is the leading
cause of nongonococcal urethritis and epididymitis
in men under 35 years of age. In women, it causes
mucopurulent cervicitis, urethral syndrome, and
pelvic inflammatory disease (PID).
The health-care costs of C. trachomatis infections
are substantial. In 1990, the direct and indirect
costs incurred with PID and PID-associated ectopic
pregnancy and infertility--medical problems fre-
quently arising from untreated, uncomplicated chla-
mydial infections--were estimated to be $4.2
billion.
The treatment of genital chlamydial infections
has been difficult. Tetracycline or doxycycline ad-
ministered orally for 7 days has been widely pre-
scribed as a first-line agent for chlamydial urethritis
and cervicitis, although the treatment is limited by
mild, bothersome side effects and frequent dosing
that can result in poor compliance. In addition, both
tetracycline and doxycycline are contraindicated in
pregnant patients. Among the macrolides, erythro-
mycin has been used in pregnant women and in
patients intolerant of tetracyclines, although it has
been poorly tolerated in dosages shown to be clini-
cally effective against C. trachomatis infection. 1’3
CHEMISTRY
Azithromycin is a 15-membered-ring macrolide
that differs from erythromycin by the presence of
a methyl-substituted nitrogen in the macrolide ring.
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TABLE I. Approved indications for azithromycin
Infection Pathogens Dosage
Nongonococcal urethritis and cervicitis
Acute bacterial exacerbation of chronic
obstructive pulmonary disease
Community-acquired pneumonia
Pharyngitis and tonsillitis
Acute otitis media
Uncomplicated skin and skin-structure infections
Chlamydia trachomatis
Streptococcus pneumoniae
Haemophilus intluenzae
Moraxella catarrhalis
S. pneumoniae
H. influenzae
S. pyogenes
S. pneumoniae
H. influenzae
M. catarrhalis
Staphylococcus aureus
S. pyogenes
S. agalactiae
Igl
500 mg day, 250 mg 4 days
500 mg day, 250 mg 4 days
500 mg day, 250 mg 4 days (adults)
12 mg/kg 5 days (children)
10 mg/kg day, 5 mg/kg 4 days (children)
500 mg day, 250 mg 4 days
aOutpatient pneumonia of mild severity.
bPenicillin is first-line therapy.
In contrast, clarithromycin and dirithromycin are
14-membered ring macrolides that are analogs of
erythromycin.
7,8
MECHANISM OF ACTION
Azithromycin, like erythromycin, produces its anti-
bacterial effects by inhibiting bacterial protein syn-
thesis through binding to the 50S ribosomal subunit
of susceptible organisms.
PHARMACOKINETICS
Azithromycin is distinguished from erythromycin
by its unique cellular kinetics, which include rapid
and extensive penetration into intracellular and in-
terstitial tissue compartments and high and sus-
tained tissue levels accompanied by relatively low
serum levels. The absorption of azithromycin is
generally more predictable than that of erythromy-
cin, producing higher tissue and intracellular con-
centrations.8’1’11 After absorption, azithromycin is
distributed rapidly from serum.
The bioavailability of azithromycin is 37%. 12 The
elimination half-life [36-40 h, as determined 24-72
h after a 500-rag intravenous (IV) dose] is more
than 10-fold that of other available macrolides. 7,12
The concentration of azithromycin in most tis-
sues exceeds that in serum by 10- to 100-fold. 12
The projected tissue levels in the prostate or uterus
following a single 1-g dose remain well above the
minimum inhibitory concentration for 90% (MICg0)
of C. trachomatis isolates for as long as 10 days (Fig.
1).1,3 In women who received a single 500-rag oral
dose of azithromycin 24-96 h before surgery, high
drug concentrations were found in gynecologic tis-
sue up to 96 h after administration. 14 The mean
maximum concentration 24 h after dosing was 1.44
Ixg/g, and the estimated tissue half-life was 67 h.
The high, sustained concentrations of azithromycin
in gynecologic tissue result in the presence of drug
above the MICg0 throughout the long life cycle of
C. trachomatis.
Delivery by phagocytes enhances the concentra-
tions of azithromycin at sites of infection. The up-
take by polymorphonuclear leukocytes (PMLs) and
alveolar or peritoneal macrophages is rapid.
15 After
2 h of incubation, the intracellular or extracellular
concentration ratio was 79 in human PMLs and 62
in murine peritoneal macrophages, compared with
erythromycin ratios of 16 and 4, respectively. After
24 h, azithromycin was concentrated 10-fold higher
than erythromycin in human PMLs and 26-fold
higher in murine peritoneal macrophages. One hour
after the removal ofextracellular erythromycin, 85%
ofthe accumulated stores were released. In contrast,
the removal of extracellular azithromycin resulted
in a slow release from intracellular stores (only 19%
after h). The exposure of the cells to bacteria
enhanced the release of azithromycin from
phagocytes.
The significance of the sustained tissue and in-
tracellular concentrations of azithromycin is re-
flected in its dosage schedule. Azithromycin is ad-
ministered in a single 1-g dose to patients with
uncomplicated urethritis or cervicitis due to C. tra-
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Fig. I. Projected tissue levels of a single I-g dose of azithromycin over 10 days (adapted from
Foulds et al. and Scieux et al.3).
chomatis. For adults with indicated respiratory-tract
or skin and skin-structure infections (see below),
azithromycin is administered on a 5-day dosage
schedulem500 mg on day 1, followed by 250 mg
once daily on days 2-5 (unpublished data, Pfizer,
Inc., 1996).
Azithromycin is also supplied as a powder for
pediatric oral suspension (unpublished data, Pfizer,
Inc., 1996). When administered at 10 mg/kg on day
followed by 5 mg/kg on days 2-5 in children 1-
15 years old, the mean pharmacokinetic parameters
at day 5 were comparable to those seen in adults.
Food increases the rate of absorption of azithro-
mycin given as the pediatric oral suspension,
whereas the extent of absorption is unchanged.
Food decreases the absorption ofthe capsule formu-
lation of azithromycin. Both capsules and the oral
suspension should be given at least h before or
2 h after a meal.
SIDE EFFECTS
Azithromycin shares the favorable overall safety
profile of erythromycin but demonstrates better
gastrointestinal tolerability. Among 2,922 adults
scheduled to receive multiple-dose azithromycin
in clinical trials, the treatment was discontinued
because of side effectsmchiefly gastrointestinal
symptoms--in 22 patients (0.8%), significantly
fewer than in erythromcyin recipients (24/450,
5.3%) or in those receiving any comparative agent
(72/2,835, 2.5%).
6 The incidence of side effects in
children was comparable to that in adults.
The most common side effects in adults receiv-
ing a single 1-g dose of azithromycin involved the
gastrointestinal system. The side effects that oc-
curred with a frequency of >-1% included diarrhea
or loose stools (7%), nausea (5%), vomiting (2%),
and vaginitis (2%) (unpublished data, Pfizer, Inc.,
1996).
Some macrolides can inhibit drug metabolism in
the liver by complex formation and inactivation of
the drug-oxidizing enzyme cytochrome P450.7 For
example, erythromycin has been associated with
clinically important interactions with concomitantly
administered drugs such as theophylline and carba-
mazepine. Azithromycin does not form covalent
chemical complexes with cytochrome 19450 en-
zymes and does not demonstrate metabolic drug
interactions with theophylline, carbamazepine, or
terfenadine. 8-2
ANTIMICROBIAL SPECTRUM
Azithromycin is highly active against erythromycin-
susceptible, gram-positive organisms because of a
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common mechanism of action. In recent surveys
of bacterial pathogens in the United States, the rates
of susceptibility to azithromycin and erythromycin
were virtually identical for clinical isolates of Strep-
tococ.cus pneumoniae, S. pyogenes, S. agalactiae, and
methicillin-susceptible Staphylococcus aureus, zl’zz
Azithromycin is substantially more potent than
other macrolides against several clinically important
gram-negative pathogens, including Haemophilus in-
fluenzae and Moraxella catarrhalis as well as Myco-
plasma pneumoniae, z3-z5
In vitro studies have shown that azithromycin
and erythromycin have comparable activity against
C. trachomatis. ’z6’z7 The MICs for azithromycin
ranged from 0.03 to 0.5 Ixg/ml in these studies,
compared with 0.03 to 1.0 g/ml for erythromycin.
CLINICAL APPLICATIONS
The approved indications and dosage schedules for
use of azithromycin are summarized in Table 1.
Recent clinical trialsz8-3 have shown that azithro-
mycin is effective and well tolerated when adminis-
tered as a single dose (1 g) in patients with uncom-
plicated urethritis or cervicitis due to C. trachomatis.
In a randomized, comparative study, men at-
tending a sexually transmitted disease (STD) clinic
who had positive cultures for C. trachomatis received
either a single 1-g dose of azithromycin or doxycy-
cline, 100 mg twice daily for 7 days. z8 After 4 weeks,
the chlamydial cultures were negative for 43 of 44
patients given azithromycin and 48 of 49 patients
given doxycycline. Azithromycin was very well tol-
erated.
A recent double-blind, multiclinic trial compared
single-dose azithromycin with the standard 7-day
doxycycline therapy in men with symptomatic non-
gonococcal urethritis, z9The cumulative clinical cure
rate was 81% among azithromycin recipients and
77% for doxycycline recipients. The cure rates were
comparable when patients were stratified by the
presence or absence of infection with C. trachomatis
prior to therapy. Among those with positive baseline
cultures, the overall microbiologic cure rates were
83% [95% confidence interval (CI), 65-94%] for
azithromycin-treated patients and 90% (95% CI,
68-98%) for doxycycline-treated patients. Gastroin-
testinal side effects, the most common adverse ex-
periences with both azithromycin and doxycycline,
occurred in 19% and 26% of patients, respectively.
In a multicenter trial,
3 299 women and 158 men
with uncomplicated genital infections (urethritis or
cervicitis) and antigen tests positive for C. tracho-
matis were randomly assigned to receive oral doses
of either azithromycin (1 g once) or doxycycline
(100 mg orally twice daily for 7 days). Only the
patients subsequently determined to have cultures
showing C. trachomatis at baseline were evaluated.
Bacteriologic eradication was achieved in 96% ofthe
evaluable patients given single-dose azithromycin,
compared with 98% of those treated with doxycy-
cline. Among the patients evaluated 21-35 days
after treatment began, the eradication rates were
100% with azithromycin and 99% with doxycycline.
Treatment-related side effects were reported in
17% of azithromycin recipients and in 20% of doxy-
cycline recipients. Gastrointestinal symptoms were
the mostcommon side effects in each group. Except
for azithromycin-treated patient with nausea, the
symptoms were mild or moderate in severity.
3
The efficacy and safety of azithromycin in preg-
nant women with chlamydial cervicitis have been
compared with those of erythromycin.
31 Patients
were randomly assigned to receive erythromycin or
azithromycin and requested to complete question-
naires identifying adverse events. The cure rates
were similar with both treatments. All patients in
the erythromycin group, however, reported 2 or
more gastrointestinal side effects, compared with
none in the azithromycin group. In addition, 5 of
15 erythromycin-treated patients were intolerant of
the 500-mg 4-times-daily dosage, requiring a reduc-
tion to 250 mg to complete the treatment course.
No azithromycin-treated patients failed to tolerate
the single 1-g oral dose. These findings suggested
that azithromycin is an effective alternative to
erythromycin in pregnant patients who are intoler-
ant of erythromycin or noncompliant because of
gastrointestinal side effects.
In randomized, multicenter trials in adults
with community-acquired respiratory-tract infec-
tions,32-34 azithromycin administered in a 5-day dos-
age regimen was compared with the standard 10-
day regimens of other agents. In all studies, the
clinical and bacteriologic efficacy of azithromycin
was similar to that of the comparative agents. The
infections included acute bacterial exacerbation of
chronic obstructive pulmonary disease (chronic
bronchitis), mild pneumonia suitable for outpatient
oral therapy, and acute pharyngitis or tonsillitis (Ta-
ble 1).
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A multicenter trial in patients with uncomplicated
skin and skin-structure infections--predominantly
cellulitis or abscesses--showed that azithromycin
administered once daily for 5 days was effective clini-
cally and bacteriologically.
35 The strains of S. aureus
and S. pyogenes were the most common bacterial
isolates.
COST
For the treatment of genital chlamydial infections,
azithromycin (1 g once) is more cost-effective than
the 7-day regimens of doxycycline. 36’37 In the treat-
ment of indicated respiratory-tract and skin and
skin-structure infections, 5-day azithromycin ther-
apy has among the lowest cost per treatment of any
branded antibiotic.38 The cost comparisons among
antimicrobial agents should consider the expected
rates of compliance and expenditures for side ef-
fects or drug interactions in addition to drug-acqui-
sition costs.38’39 A lack of compliance can lead to
treatment failure and an increase in the cost of
therapy.
4 Further, adverse effects may increase the
treatment costs regardless of any effect on com-
pliance,
s8
Compliance is particularly important in the treat-
ment ofchlamydial STDs because an asymptomatic
infection, which is common, often involves a sexual
partnerwho may be insufficiently motivated to seek
medical attention or receive therapy. Among pa-
tients treated with the standard 7-day regimens at
an STD clinic, compliance has been estimated at
60%.4 Additional studies are required to determine
whether noncompliance with the 7-day doxycycline
treatment results in a high rate of therapeutic fail-
ure.42 Single-dose therapy with azithromycin would
most likely ensure a 100% rate of compliance,s
CONCLUSIONS
Azithromycin, the first member of the azalide sub-
class of macrolide antibiotics, is distinguished from
other macrolides by its extensive penetration into
intracellular and interstitial tissue compartments.
Although it shares the gram-positive activity of
erythromycin, azithromycin is substantially more
potent against gram-negative organisms. The pro-
longed half-life in serum and tissues allows a 5-
day, once-daily dosage schedule in the treatment
of indicated respiratory-tract and skin and skin-
structure infections (unpublished data, Pfizer,
Inc., 1996).
Azithromycin, g orally in a single dose, has
been recommended by the CDC for the treatment
of chlamydial infections, along with the previously
recommended regimen of doxycycline, 100 mg
orally twice daily for 7 days.42 Ofloxacin, 300 mg
orally twice daily for 7 days, and the older erythro-
mycin regimens are alternatives. A single dose of
azithromycin is less expensive than a 7-day regimen
of doxycycline or ofloxacin.
Azithromycin has demonstrated better gastroin-
testinal tolerability than erythromycin.
6 In addition,
azithromycin, a pregnancy category-B drug, may be
a valid alternative to erythromycin in pregnant pa-
tients (unpublished data, Pfizer, Inc., 1996).
3
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